Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Effect of taVNS and Upper GI Motility

2 giugno 2026 aggiornato da: Daniel Keszthelyi

The Effect of Non-invasive Transauricular Vagus Nerve Stimulation on Upper Gastrointestinal Motility in Healthy Individuals

This single-center randomized controlled cross-over trial aims to investigate the effect of transcutaneous auricular vagus nerve stimulation on upper gastrointestinal motility in healthy individuals.

The primary aim of this study is to assess the impact of tVNS on gut motor function, with regards to its potential to induce phase III contractions in the upper GI tract.

Secondary objectives include:

  • To study the effect of tVNS on other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
  • To study the effect of tVNS on plasma levels of motilin and PP
  • To evaluate the effect of tVNS on parameters related to autonomic outflow, using a Shimmer3 GSR Sensor for heart rate variability and skin conductance.
  • To compare the results of the measurements of antroduodenal manometry with measurements of Gastric Alimetry

Participants will undergo tVNS (applied to the cymba conchae of the left ear) alternating with sham stimulation (using a non-conducting electrode) in a blinded, pre-randomized fashion, using two 4-hour blocks during an 8-hour fasted antroduodenal manometry recording period. Optionally, participants may simultaneously also undergo body surface gastric mapping using the Gastric Alimetry system.

Panoramica dello studio

Descrizione dettagliata

Visit 1 (screening visit) Following written informed consent, the medical history of each subject will be checked during a structured interview. A pregnancy will be excluded by a urine test (due to the use or fluoroscopy during insertion of the manometry catheter) and a 12-lead ECG will be performed at the end of the screening visit. The rationale for this is to ensure no evidence of cardiac conduction disorders and an additional safety step to ensure no cardiac dysrhythmic affect with tVNS use. All information obtained during the screening visit will be recorded in using an electronic CRF provided by Castor EDC, provided by the Clinical Trial Centre Maastricht (CTCM).

Visit 2 (test day) Participants will arrive after an overnight fast at the GI physiology unit of the Maastricht University Medical Center, where a trained and experienced nurse will insert an antroduodenal manometry catheter through the nose into the duodenum under fluoroscopy control and supervision of a gastroenterologist (as per routine clinical procedure). Using this catheter, stomach and duodenum motility patterns will be recorded for 8 hours. After the manometry is inserted, the tVNS device will be connected with an electrode which delivers stimulation transcutaneous in the outer ear. Participants will receive two types of stimulation (i.e. tVNS vs sham) in 2 blocks of 4 hours during the 8-hour registration period. The order of stimulation applied is randomized. Gastric phase III contractions generally occur every 90 minutes, so the 4-hour period is considered sufficient to detect two phase III contractions considered sufficient to detect the two phase III contractions.(10)

An iv catheter will be inserted to draw blood during the 8-hour registration period. Blood samples, each witch a maximum volume of 10 mL, will be taken every 30 minutes to measure motilin and PP as surrogate markers of vagal efferent influence on GI motor function. In addition, autonomic parameters will be registered during the entire test period, using a Shimmer3 GSR sensor. After the 8-hour test period, the manometry catheter, the electrodes of the tVNS device and the iv cannula are removed.

Additionally, participants may opt to take part in a body surface gastric mapping assessment. This non-invasive, electrophysiological measurement is performed using the Gastric Alimetry system, which involves placing a large adhesive patch with multiple electrodes on the upper abdomen. The system records gastric myoelectrical activity over time, providing insight into gastric motility patterns. The measurement is conducted concurrently with the manometry registration period.

Tipo di studio

Interventistico

Iscrizione (Stimato)

12

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Limburg
      • Maastricht, Limburg, Olanda, 6229ER
        • Reclutamento
        • Maastricht University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto

Accetta volontari sani

Descrizione

Inclusion Criteria:

  • Healthy participants (defined as those without a pre-existing medical comorbidity, including those without a history of cardiac arrhythmia).
  • Age between 18 and 55 years.
  • Ability to understand and speak the Dutch language.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Use of any substances (such as medication or recreational drugs) influencing gastrointestinal motility
  • Not meeting the inclusion criteria above.
  • Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional of hierarchical position with regards to any of the study team members or their department.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Transcutaneous Auricular Vagal Nerve Stimulation
TaVNS
taVNS will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.
Comparatore placebo: Sham stimulation
Sham stimulation with a non-conducting electrode
Sham stimulation will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
A clinically meaningful increase in phase III contractions
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically meaningful increase in the number of phase III contractions of antral origin in the fasted period during the tVNS stimulation compared to the sham stimulation.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
A clinically relevant increase in other upper GI motility parameters
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically relevant increase in other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Concentration of plasma motilin and pancreatic polypeptide
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in plasma motilin and pancreatic polypeptide following taVNS vs. sham stimulation
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Autonomic response: heart rate variability
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in heart rate variability measured continuously using a Shimmer3 GSR sensor
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Electrodermal response: skin conductance
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in skin conductance following taVNS vs sham stimulation, assessed continuously using a Shimmer3 GSR sensor.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between gastric motility measurements obtained by antroduodenal manometry and Gastric Alimetry
Lasso di tempo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between antroduodenal manometry and Gastric Alimetry measurements obtained simultaneously.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Daniel Keszthelyi, MD, PhD, Maastricht University Medical Center

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 febbraio 2025

Completamento primario (Stimato)

1 giugno 2026

Completamento dello studio (Stimato)

1 giugno 2026

Date di iscrizione allo studio

Primo inviato

26 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

2 giugno 2026

Primo Inserito (Effettivo)

8 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Vagal Nerve Stimulation

Sottoscrivi